Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free, produced by co-expression of ITGAV and ITGB3, has a calculated MW of 112.9 kDa (ITGAV) and 81.8 kDa (ITGB3). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and subunit ITGB3 contains no tag but a basic tail at the C-terminus. The non-reducing (NR) protein migrates as 130-150 kDa (ITGAV) and 90-100 kDa (ITGB3) respectively due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52E3) is more than 85% and the molecular weight of this protein is around 207-253 kDa verified by SEC-MALS.
Immobilized Human Fibronectin at 2 μg/mL (100 μL/well) can bind Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52E3) with a linear range of 0.01-0.3 μg/mL (QC tested).
Authors: Naoya Kondo, et al
Journal: Biochem Biophys Res Commun 2020
Application: Selectivity Assay
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.